Technology ID
TAB-4575
Intranasal or Inhaled Delivery of a Custom IgA Antibody for Protection Against COVID-19
E-Numbers
E-007-2021-0
Lead Inventor
Sadtler, Kaitlyn (NIBIB)
Co-Inventors
Memoli, Mathew (NIAID)
Applications
Therapeutics
Therapeutic Areas
Infectious Disease
Development Stages
Pre-Clinical (in vitro)
Research Products
Antibodies
Lead IC
NIBIB
ICs
NIBIB
NIAID
This technology includes an IgA antibody, specifically designed to target the receptor binding domain of SARS-CoV-2, the virus causing COVID-19. Administered intranasally, this antibody has potential neutralizing activity, aiming to prevent COVID-19. IgA, an antibody class present in mucosal areas, plays a crucial role in immune defense at the initial site of viral infection. The primary application of this technology is envisioned as a therapeutic nasal spray, intended to prevent SARS-CoV-2 infection, particularly in high-risk populations. This approach represents a targeted method to bolster defenses against COVID-19 at its point of entry in the human body.
Commercial Applications
The potential application of this technology is the development of a therapeutic nasal spray designed to prevent SARS-CoV-2 infection, with a focus on safeguarding high-risk populations from COVID-19.
Competitive Advantages
The competitive advantage of this technology lies in its specificity, as it targets the receptor binding domain of SARS-CoV-2, increasing its potential to neutralize the virus at its point of entry through intranasal administration. This approach harnesses the protective properties of IgA antibodies, strategically deploying them in mucosal areas to enhance the initial immune defense against COVID-19, particularly benefitting high-risk populations.
Licensing Contact: